CervoMed Inc. announced on September 17, 2025, that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted at the 150th Annual American Neurological Association (ANA) conference. Dr. James Galvin presented on advances in DLB drug development.
The presentation showcased positive data from the Phase 2b trial, including a 74% risk reduction relative to placebo in patients who have a low likelihood of having concomitant Alzheimer's Disease (AD) pathology. This further reinforces neflamapimod's disease-modifying benefit.
CervoMed is actively preparing to begin a Phase 3 trial in DLB patients and expects to reach alignment on the design of that trial with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. This highlights the company's focus on rapidly advancing this therapeutic agent for a disease with profound unmet need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.